{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015299","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.069692+00:00","generated_at":"2026-05-30T01:58:43.631716+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025","bullets":["Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.","Licensed TRACER capsid to Novartis for undisclosed rare neurologic target; $15M upfront, up to $305M milestones.","Neurocrine partnership selected 3rd development candidate, triggering $3M milestone.","VY7523 anti-tau antibody SAD trial enrollment complete; top-line safety/PK data expected H1 2025.","Cash $345.4M at Sep 30; plus $18M received in Oct; runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015299","json":"https://secwatch.observer/filing/0001558370-24-015299.json","markdown":"https://secwatch.observer/filing/0001558370-24-015299.md","text":"https://secwatch.observer/filing/0001558370-24-015299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024015299/0001558370-24-015299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024015299/vygr-20241112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:58:43.631716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}